Utility Therapeutics Ltd.

The disruption of existing markets is a dominant ambition of the nearly 20 applications expecting US Food and Drug Administration action in March. The Pink Sheet ’s US FDA Performance Tracker shows

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the

GSK’s gepotidacin has been put on the regulatory fast track in the US, raising hopes that it could be the first in a new class of oral antibiotic treatment for uncomplicated urinary tract infections (

Rare diseases are almost certain to remain one of the biggest areas for novel drug development in 2024, but the orphan drug pipeline will be making space for some novel therapies for common conditions